# Entegris Inc: financial statements, quarterly

ENTG · Nasdaq · CIK 1101302 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/entg.md) · [Financials](/companies/entg/financials.md) · [Filings](/companies/entg/filings.md) · [Insiders](/companies/entg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/entg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) | Q3 FY2026 (2026-09-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [812](/filings/0001101302-24-000009.md) | [771](/filings/0001101302-25-000060.md) | [813](/filings/0001101302-25-000079.md) | [808](/filings/0001101302-25-000103.md) | [850 d](/filings/0001101302-26-000012.md) | [773](/filings/0001101302-26-000102.md) | [792](/filings/0001101302-26-000150.md) | [807](/filings/0001101302-26-000162.md) | [824 d](/filings/0001101302-26-000012.md) | [812](/filings/0001101302-26-000102.md) | [883](/filings/0001101302-26-000150.md) | [1,006](/filings/0001101302-26-000162.md) |
| Cost of revenue | $m | [468 d](/filings/0001101302-26-000012.md) | [419](/filings/0001101302-25-000060.md) | [437](/filings/0001101302-25-000079.md) | [436](/filings/0001101302-25-000103.md) | [463 d](/filings/0001101302-26-000012.md) | [417](/filings/0001101302-26-000102.md) | [441](/filings/0001101302-26-000150.md) | [456](/filings/0001101302-26-000162.md) | [463 d](/filings/0001101302-26-000012.md) | [431](/filings/0001101302-26-000102.md) | [463](/filings/0001101302-26-000150.md) | [506](/filings/0001101302-26-000162.md) |
| Gross profit | $m | [345](/filings/0001101302-24-000009.md) | [352](/filings/0001101302-25-000060.md) | [376](/filings/0001101302-25-000079.md) | [372](/filings/0001101302-25-000103.md) | [387 d](/filings/0001101302-26-000012.md) | [357](/filings/0001101302-26-000102.md) | [352](/filings/0001101302-26-000150.md) | [351](/filings/0001101302-26-000162.md) | [361 d](/filings/0001101302-26-000012.md) | [381](/filings/0001101302-26-000102.md) | [420](/filings/0001101302-26-000150.md) | [500](/filings/0001101302-26-000162.md) |
| Research and development | $m | [67.6 d](/filings/0001101302-26-000012.md) | [71.8](/filings/0001101302-25-000060.md) | [81.9](/filings/0001101302-25-000079.md) | [80.9](/filings/0001101302-25-000103.md) | [81.5 d](/filings/0001101302-26-000012.md) | [84.8](/filings/0001101302-26-000102.md) | [84.3](/filings/0001101302-26-000150.md) | [80.9](/filings/0001101302-26-000162.md) | [79.0 d](/filings/0001101302-26-000012.md) | [75.3](/filings/0001101302-26-000102.md) | [82.8](/filings/0001101302-26-000150.md) | [87.5](/filings/0001101302-26-000162.md) |
| Selling, general and administrative | $m | [145 d](/filings/0001101302-26-000012.md) | [112](/filings/0001101302-25-000060.md) | [116](/filings/0001101302-25-000079.md) | [109](/filings/0001101302-25-000103.md) | [110 d](/filings/0001101302-26-000012.md) | [103](/filings/0001101302-26-000102.md) | [115](/filings/0001101302-26-000150.md) | [102](/filings/0001101302-26-000162.md) | [130 d](/filings/0001101302-26-000012.md) | [118](/filings/0001101302-26-000102.md) | [127](/filings/0001101302-26-000150.md) | [137](/filings/0001101302-26-000162.md) |
| Operating income | $m | [101 d](/filings/0001101302-26-000012.md) | [118](/filings/0001101302-25-000060.md) | [130](/filings/0001101302-25-000079.md) | [136](/filings/0001101302-25-000103.md) | [150 d](/filings/0001101302-26-000012.md) | [122](/filings/0001101302-26-000102.md) | [106](/filings/0001101302-26-000150.md) | [123](/filings/0001101302-26-000162.md) | [105 d](/filings/0001101302-26-000012.md) | [142](/filings/0001101302-26-000102.md) | [165](/filings/0001101302-26-000150.md) | [231](/filings/0001101302-26-000162.md) |
| Interest expense | $m | [67.5 d](/filings/0001101302-25-000015.md) | [57.4](/filings/0001101302-25-000060.md) | [53.7](/filings/0001101302-25-000079.md) | [51.7](/filings/0001101302-24-000074.md) | [52.5 d](/filings/0001101302-25-000015.md) | [51.0](/filings/0001101302-25-000060.md) | [52.4](/filings/0001101302-25-000079.md) | [47.9](/filings/0001101302-26-000162.md) | [48.5 d](/filings/0001101302-26-000012.md) | [48.9](/filings/0001101302-26-000102.md) | [48.6](/filings/0001101302-26-000150.md) | [45.4](/filings/0001101302-26-000162.md) |
| Income tax | $m | [(11.3) d](/filings/0001101302-26-000012.md) | [3.4](/filings/0001101302-25-000060.md) | [6.7](/filings/0001101302-25-000079.md) | [8.2](/filings/0001101302-25-000103.md) | [10.0 d](/filings/0001101302-26-000012.md) | [8.2](/filings/0001101302-26-000102.md) | [2.8](/filings/0001101302-26-000150.md) | [1.5](/filings/0001101302-26-000162.md) | [5.5 d](/filings/0001101302-26-000012.md) | [1.0](/filings/0001101302-26-000102.md) | [16.5](/filings/0001101302-26-000150.md) | [28.7](/filings/0001101302-26-000162.md) |
| Net income | $m | [38.0](/filings/0001101302-24-000009.md) | [45.3](/filings/0001101302-25-000103.md) | [67.7](/filings/0001101302-25-000103.md) | [77.5](/filings/0001101302-25-000103.md) | [102 d](/filings/0001101302-26-000012.md) | [62.9](/filings/0001101302-26-000162.md) | [52.8](/filings/0001101302-26-000162.md) | [70.5](/filings/0001101302-26-000162.md) | [49.4 d](/filings/0001101302-26-000012.md) | [92.0](/filings/0001101302-26-000162.md) | [93.6](/filings/0001101302-26-000162.md) | [158](/filings/0001101302-26-000162.md) |
| Diluted EPS | $ per share | [0.25](/filings/0001101302-24-000009.md) | [0.30](/filings/0001101302-25-000060.md) | [0.45](/filings/0001101302-25-000079.md) | [0.51](/filings/0001101302-25-000103.md) | not reported | [0.41](/filings/0001101302-26-000102.md) | [0.35](/filings/0001101302-26-000150.md) | [0.46](/filings/0001101302-26-000162.md) | not reported | [0.60](/filings/0001101302-26-000102.md) | [0.61](/filings/0001101302-26-000150.md) | [1.03](/filings/0001101302-26-000162.md) |
| Basic EPS | $ per share | [0.25](/filings/0001101302-24-000009.md) | [0.30](/filings/0001101302-25-000060.md) | [0.45](/filings/0001101302-25-000079.md) | [0.51](/filings/0001101302-25-000103.md) | not reported | [0.42](/filings/0001101302-26-000102.md) | [0.35](/filings/0001101302-26-000150.md) | [0.46](/filings/0001101302-26-000162.md) | not reported | [0.60](/filings/0001101302-26-000102.md) | [0.61](/filings/0001101302-26-000150.md) | [1.03](/filings/0001101302-26-000162.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) | Q3 FY2026 (2026-09-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [457](/filings/0001101302-25-000015.md) | [341](/filings/0001101302-24-000040.md) | [320](/filings/0001101302-24-000053.md) | [432](/filings/0001101302-24-000074.md) | [329](/filings/0001101302-26-000012.md) | [341](/filings/0001101302-25-000060.md) | [377](/filings/0001101302-25-000079.md) | [400](/filings/0001101302-25-000103.md) | [360](/filings/0001101302-26-000162.md) | [443](/filings/0001101302-26-000102.md) | [354](/filings/0001101302-26-000150.md) | [357](/filings/0001101302-26-000162.md) |
| Current assets | $m | [1,977](/filings/0001101302-25-000015.md) | [1,575](/filings/0001101302-24-000040.md) | [1,577](/filings/0001101302-24-000053.md) | [1,715](/filings/0001101302-24-000074.md) | [1,616](/filings/0001101302-26-000012.md) | [1,670](/filings/0001101302-25-000060.md) | [1,706](/filings/0001101302-25-000079.md) | [1,697](/filings/0001101302-25-000103.md) | [1,638](/filings/0001101302-26-000162.md) | [1,786](/filings/0001101302-26-000102.md) | [1,785](/filings/0001101302-26-000150.md) | [1,921](/filings/0001101302-26-000162.md) |
| Total assets | $m | [8,813](/filings/0001101302-25-000015.md) | [8,365](/filings/0001101302-24-000040.md) | [8,337](/filings/0001101302-24-000053.md) | [8,473](/filings/0001101302-24-000074.md) | [8,395](/filings/0001101302-26-000012.md) | [8,431](/filings/0001101302-25-000060.md) | [8,450](/filings/0001101302-25-000079.md) | [8,402](/filings/0001101302-25-000103.md) | [8,351](/filings/0001101302-26-000162.md) | [8,475](/filings/0001101302-26-000102.md) | [8,419](/filings/0001101302-26-000150.md) | [8,541](/filings/0001101302-26-000162.md) |
| Current liabilities | $m | [514](/filings/0001101302-25-000015.md) | [470](/filings/0001101302-24-000040.md) | [440](/filings/0001101302-24-000053.md) | [587](/filings/0001101302-24-000074.md) | [525](/filings/0001101302-26-000012.md) | [513](/filings/0001101302-25-000060.md) | [517](/filings/0001101302-25-000079.md) | [493](/filings/0001101302-25-000103.md) | [489](/filings/0001101302-26-000162.md) | [556](/filings/0001101302-26-000102.md) | [585](/filings/0001101302-26-000150.md) | [722](/filings/0001101302-26-000162.md) |
| Long-term debt | $m | [4,577](/filings/0001101302-25-000015.md) | [4,173](/filings/0001101302-24-000040.md) | [4,122](/filings/0001101302-24-000053.md) | [4,061](/filings/0001101302-24-000074.md) | [3,981](/filings/0001101302-26-000012.md) | [3,985](/filings/0001101302-25-000060.md) | [3,938](/filings/0001101302-25-000079.md) | [3,843](/filings/0001101302-25-000103.md) | [3,698](/filings/0001101302-26-000162.md) | [3,651](/filings/0001101302-26-000102.md) | [3,456](/filings/0001101302-26-000150.md) | [3,261](/filings/0001101302-26-000162.md) |
| Current portion of debt | $m | [0.0](/filings/0001101302-25-000015.md) | [0.0](/filings/0001101302-24-000040.md) | [0.0](/filings/0001101302-24-000053.md) | [65.0](/filings/0001101302-24-000074.md) | [0.0](/filings/0001101302-25-000103.md) | not reported | [50.0](/filings/0001101302-25-000079.md) | [0.0](/filings/0001101302-25-000103.md) | [0.0](/filings/0001101302-26-000150.md) | [0.0](/filings/0001101302-26-000102.md) | [0.0](/filings/0001101302-26-000150.md) | not reported |
| Shareholders' equity | $m | [3,409](/filings/0001101302-26-000012.md) | [3,430](/filings/0001101302-25-000103.md) | [3,502](/filings/0001101302-25-000103.md) | [3,593](/filings/0001101302-25-000103.md) | [3,692](/filings/0001101302-26-000162.md) | [3,749](/filings/0001101302-26-000162.md) | [3,809](/filings/0001101302-26-000162.md) | [3,891](/filings/0001101302-26-000162.md) | [3,953](/filings/0001101302-26-000162.md) | [4,049](/filings/0001101302-26-000162.md) | [4,156](/filings/0001101302-26-000162.md) | [4,333](/filings/0001101302-26-000162.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) | Q3 FY2026 (2026-09-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [158 d](/filings/0001101302-26-000012.md) | [147](/filings/0001101302-25-000060.md) | [111 d](/filings/0001101302-25-000079.md) | [197 d](/filings/0001101302-25-000103.md) | [176 d](/filings/0001101302-26-000012.md) | [140](/filings/0001101302-26-000102.md) | [114 d](/filings/0001101302-26-000150.md) | [250 d](/filings/0001101302-26-000162.md) | [192 d](/filings/0001101302-26-000012.md) | [183](/filings/0001101302-26-000102.md) | [156 d](/filings/0001101302-26-000150.md) | [267 d](/filings/0001101302-26-000162.md) |
| Capital expenditure | $m | [129 d](/filings/0001101302-26-000012.md) | [66.6](/filings/0001101302-25-000060.md) | [59.3 d](/filings/0001101302-25-000079.md) | [82.2 d](/filings/0001101302-25-000103.md) | [108 d](/filings/0001101302-26-000012.md) | [108](/filings/0001101302-26-000102.md) | [66.5 d](/filings/0001101302-26-000150.md) | [66.7 d](/filings/0001101302-26-000162.md) | [58.0 d](/filings/0001101302-26-000012.md) | [41.5](/filings/0001101302-26-000102.md) | [39.3 d](/filings/0001101302-26-000150.md) | [43.2 d](/filings/0001101302-26-000162.md) |
| Dividends paid | $m | [15.0 d](/filings/0001101302-26-000012.md) | [15.3](/filings/0001101302-25-000060.md) | [15.1 d](/filings/0001101302-25-000079.md) | [15.1 d](/filings/0001101302-25-000103.md) | [15.1 d](/filings/0001101302-26-000012.md) | [15.4](/filings/0001101302-26-000102.md) | [15.2 d](/filings/0001101302-26-000150.md) | [15.1 d](/filings/0001101302-26-000162.md) | [15.1 d](/filings/0001101302-26-000012.md) | [15.4](/filings/0001101302-26-000102.md) | [15.4 d](/filings/0001101302-26-000150.md) | [15.4 d](/filings/0001101302-26-000162.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2023-04-01) | Q2 FY2023 (2023-07-01) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-30) | Q2 FY2024 (2024-06-29) | Q3 FY2024 (2024-09-28) | Q1 FY2025 (2025-03-29) | Q2 FY2025 (2025-06-28) | Q3 FY2025 (2025-09-27) | Q1 FY2026 (2026-03-28) | Q2 FY2026 (2026-06-27) | Q3 FY2026 (2026-09-26) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [149](/filings/0001101302-24-000040.md) | [151](/filings/0001101302-24-000053.md) | [151](/filings/0001101302-24-000074.md) | [152](/filings/0001101302-25-000060.md) | [152](/filings/0001101302-25-000079.md) | [152](/filings/0001101302-25-000103.md) | [152](/filings/0001101302-26-000102.md) | [152](/filings/0001101302-26-000150.md) | [152](/filings/0001101302-26-000162.md) | [153](/filings/0001101302-26-000102.md) | [154](/filings/0001101302-26-000150.md) | [154](/filings/0001101302-26-000162.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 152,800,000 at 2026-10-26, from the cover of the [10-Q filed 2026-10-29](/filings/0001101302-26-000162.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 31, 2026, 15:25 ET. No prices; not investment advice.